$1,129MIllumina Q3 revenue, up 4.2%
29%NeoGenomics NGS revenue growth in Q3
16 of 20top pharma companies using Proscia
Earnings & Commercial
Illumina raises 2026 guidance
Q3 revenue of $1,129M beat its own guidance on healthy clinical demand and NovaSeq X placements. Full-year revenue now seen at $4.64B to $4.66B.
Read the full story →NeoGenomics grows clinical revenue 13%
NGS revenue up 29% and guidance raised. Management plans more investment in commercial teams ahead of Warren Stone taking over as CEO in January.
Read the full story →Why it matters: in both results, the growth is coming from clinical sequencing, not research budgets.
Regulatory & Testing
Tempus wins EU IVDR certification for xR
Its RNA sequencing assay for solid tumours is now a certified Class C device, keeping it available in the EU beyond the 2028 transition deadline.
Read the full story →Digital Pathology
Proscia and Columbia partner on dementia biomarkers
Pathology AI meets Columbia's slide archive to find and validate biomarkers for Alzheimer's and other dementias. Agilent agreed to buy Proscia earlier this month.
Read the full story →Talent Insight
The clinical shift is changing who companies need
- When growth comes from clinical labs, the sought-after profiles change: field application scientists, account managers and service engineers who know validated clinical workflows.
- Coverage wins and in-network payer deals make reimbursement and market access people a bigger lever on growth than another sales rep.
- For Europe: people with hands-on IVDR experience remain scarce, and every certification makes the next company keener to hire them.
Building a team in Genomics & Diagnostics?
Eric Sharma specialises in Genomics & Diagnostics hiring at QP Group. Talk to Eric about the market, salaries or a search.
Eric SharmaBusiness Consultant · Multi-Omics & Diagnostics